​​Prostate Cancer: Key Insights from AUA 2025 скачать в хорошем качестве

​​Prostate Cancer: Key Insights from AUA 2025

In a discussion with Adam B. Weiner, MD, a urologist at Cedars Sinai Medical Center, key insights emerged from several compelling prostate cancer abstracts presented at the American Urological Association (AUA) 2025 Annual Meeting. One notable trend, highlighted in MP22-01, is the encouraging decline in the surgical overtreatment of prostate cancer. This suggests a positive shift towards more judicious and personalized treatment approaches, potentially driven by improved diagnostic tools and a greater understanding of disease heterogeneity. The ARANOTE trial (NCT04736199), as detailed in MP16-01, demonstrated the efficacy and safety of darolutamide (Nubeqa) plus androgen-deprivation therapy (ADT) in Black patients with metastatic hormone-sensitive prostate cancer (mHSPC). This is a significant finding, addressing disparities in prostate cancer outcomes and offering a valuable treatment option for this patient population. An interesting post hoc analysis of the EMBARK trial (PD13-03) explored testosterone recovery following treatment suspension of enzalutamide (Xtandi) plus leuprolide or leuprolide alone in patients with high-risk biochemically recurrent prostate cancer. Findings presented at the meeting showed that most male patients receiving treatment with either enzalutamide plus leuprolide acetate or placebo plus leuprolide acetate had a complete recovery of testosterone following suspension of the treatment at 36 weeks. Finally, MP07-01 presented results from a phase 2 trial of neoadjuvant niraparib (Zejula) in men with DNA repair gene deficient clinically localized prostate cancer. This study offers early insights into the potential role of PARP inhibitors in the localized setting for patients with specific genomic alterations, paving the way for more targeted therapies. Weiner's expert perspective underscores the dynamic nature of prostate cancer research, with advancements continually refining our approach to diagnosis and treatment. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/